The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy

Dan V Iosifescu,1 Robert J Neborsky,2–4 Robert J Valuck5–7 1Adult Psychopharmacology Program, Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2School of Medicine, University of California, San Diego, CA, USA; 3University of California, Los...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iosifescu DV, Neborsky RJ, Valuck RJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	EEG Depression Antidepressant Suicide Predictive Analytics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9a66b6c7e65449ba8d160e01666bda91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a66b6c7e65449ba8d160e01666bda91
record_format	dspace
spelling	oai:doaj.org-article:9a66b6c7e65449ba8d160e01666bda912021-12-02T02:07:07ZThe use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy1178-2021https://doaj.org/article/9a66b6c7e65449ba8d160e01666bda912016-08-01T00:00:00Zhttps://www.dovepress.com/the-use-of-the-psychiatric-electroencephalography-evaluation-registry--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Dan V Iosifescu,1 Robert J Neborsky,2–4 Robert J Valuck5–7 1Adult Psychopharmacology Program, Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2School of Medicine, University of California, San Diego, CA, USA; 3University of California, Los Angeles, CA, USA; 4Medical Corps, US Navy, USA; 5Pharmacy, Epidemiology, and Family Medicine, University of Colorado, Denver, CO, USA; 6Center for Pharmaceutical Outcomes Research, University of Colorado, Denver, CO, USA; 7Colorado Consortium for Prescription Drug Abuse Prevention, Denver, CO, USA Purpose: This study aims to determine whether Psychiatric Electroencephalography Evaluation Registry (PEER) Interactive (an objective, adjunctive tool based on a comparison of a quantitative electroencephalogram to an existing registry of patient outcomes) is more effective than the current standard of care in treatment of subjects suffering from depression. Patients and methods: This is an interim report of an ongoing, 2-year prospective, randomized, double blind, controlled study to evaluate PEER Interactive in guiding medication selection in subjects with a primary diagnosis of depression vs standard treatment. Subjects in treatment at two military hospitals were blinded as to study group assignment and their self-report symptom ratings were also blinded. Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16) depression scores were the primary efficacy endpoint. One hundred and fifty subjects received a quantitative electroencephalography exam and were randomized to either treatment as usual or PEER-informed pharmacotherapy. Subjects in the control group were treated according to Veterans Administration/Department of Defense Guidelines, the current standard of care. In the experimental group, the attending physician received a PEER report ranking the subject’s likely clinical response to on-label medications. Results: In this post hoc interim analysis subjects were separated into Report Followed and Report Not Followed groups – based on the concordance between their subsequent treatment and PEER medication guidance. We thus evaluated the predictive validity of PEER recommendations. We found significantly greater improvements in depression scores (QIDS-SR16 P<0.03), reduction in suicidal ideation (Concise Health Risk Tracking Scale-SR7 P<0.002), and post-traumatic stress disorder (PTSD) score improvement (PTSD Checklist Military/Civilian P<0.04) for subjects treated with PEER-recommended medications compared to those who did not follow PEER recommendations. Conclusion: This interim analysis suggests that an objective tool such as PEER Interactive can help improve medication selection. Consistent with results of earlier studies, it supports the hypothesis that PEER-guided treatment offers distinct advantages over the current standard of care. Keywords: EEG, depression, antidepressant, suicide, predictive analyticsIosifescu DVNeborsky RJValuck RJDove Medical PressarticleEEGDepressionAntidepressantSuicidePredictive AnalyticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 12, Pp 2131-2142 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	EEG Depression Antidepressant Suicide Predictive Analytics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	EEG Depression Antidepressant Suicide Predictive Analytics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Iosifescu DV Neborsky RJ Valuck RJ The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
description	Dan V Iosifescu,1 Robert J Neborsky,2–4 Robert J Valuck5–7 1Adult Psychopharmacology Program, Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2School of Medicine, University of California, San Diego, CA, USA; 3University of California, Los Angeles, CA, USA; 4Medical Corps, US Navy, USA; 5Pharmacy, Epidemiology, and Family Medicine, University of Colorado, Denver, CO, USA; 6Center for Pharmaceutical Outcomes Research, University of Colorado, Denver, CO, USA; 7Colorado Consortium for Prescription Drug Abuse Prevention, Denver, CO, USA Purpose: This study aims to determine whether Psychiatric Electroencephalography Evaluation Registry (PEER) Interactive (an objective, adjunctive tool based on a comparison of a quantitative electroencephalogram to an existing registry of patient outcomes) is more effective than the current standard of care in treatment of subjects suffering from depression. Patients and methods: This is an interim report of an ongoing, 2-year prospective, randomized, double blind, controlled study to evaluate PEER Interactive in guiding medication selection in subjects with a primary diagnosis of depression vs standard treatment. Subjects in treatment at two military hospitals were blinded as to study group assignment and their self-report symptom ratings were also blinded. Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16) depression scores were the primary efficacy endpoint. One hundred and fifty subjects received a quantitative electroencephalography exam and were randomized to either treatment as usual or PEER-informed pharmacotherapy. Subjects in the control group were treated according to Veterans Administration/Department of Defense Guidelines, the current standard of care. In the experimental group, the attending physician received a PEER report ranking the subject’s likely clinical response to on-label medications. Results: In this post hoc interim analysis subjects were separated into Report Followed and Report Not Followed groups – based on the concordance between their subsequent treatment and PEER medication guidance. We thus evaluated the predictive validity of PEER recommendations. We found significantly greater improvements in depression scores (QIDS-SR16 P<0.03), reduction in suicidal ideation (Concise Health Risk Tracking Scale-SR7 P<0.002), and post-traumatic stress disorder (PTSD) score improvement (PTSD Checklist Military/Civilian P<0.04) for subjects treated with PEER-recommended medications compared to those who did not follow PEER recommendations. Conclusion: This interim analysis suggests that an objective tool such as PEER Interactive can help improve medication selection. Consistent with results of earlier studies, it supports the hypothesis that PEER-guided treatment offers distinct advantages over the current standard of care. Keywords: EEG, depression, antidepressant, suicide, predictive analytics
format	article
author	Iosifescu DV Neborsky RJ Valuck RJ
author_facet	Iosifescu DV Neborsky RJ Valuck RJ
author_sort	Iosifescu DV
title	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
title_short	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
title_full	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
title_fullStr	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
title_full_unstemmed	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
title_sort	use of the psychiatric electroencephalography evaluation registry (peer) to personalize pharmacotherapy
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/9a66b6c7e65449ba8d160e01666bda91
work_keys_str_mv	AT iosifescudv theuseofthepsychiatricelectroencephalographyevaluationregistrypeertopersonalizepharmacotherapy AT neborskyrj theuseofthepsychiatricelectroencephalographyevaluationregistrypeertopersonalizepharmacotherapy AT valuckrj theuseofthepsychiatricelectroencephalographyevaluationregistrypeertopersonalizepharmacotherapy AT iosifescudv useofthepsychiatricelectroencephalographyevaluationregistrypeertopersonalizepharmacotherapy AT neborskyrj useofthepsychiatricelectroencephalographyevaluationregistrypeertopersonalizepharmacotherapy AT valuckrj useofthepsychiatricelectroencephalographyevaluationregistrypeertopersonalizepharmacotherapy
_version_	1718402722365964288

The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy

Ejemplares similares